Literature DB >> 31471882

Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations.

Mária Gregová1, Jan Hojný1, Kristýna Němejcová1, Michaela Bártů1, Michal Mára2, Barbora Boudová2, Jan Laco3, Lukáš Krbal3, Ivana Tichá4, Pavel Dundr5.   

Abstract

Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.

Entities:  

Keywords:  Fumarate hydratase; Leiomyoma with bizarre nuclei; Leiomyosarcoma; Usual leiomyoma

Mesh:

Substances:

Year:  2019        PMID: 31471882     DOI: 10.1007/s12253-019-00739-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  6 in total

1.  Uterine cellular leiomyomas are characterized by common HMGA2 aberrations, followed by chromosome 1p deletion and MED12 mutation: morphological, molecular, and immunohistochemical study of 52 cases.

Authors:  Pavel Dundr; Mária Gregová; Jan Hojný; Eva Krkavcová; Romana Michálková; Kristýna Němejcová; Michaela Bártů; Nikola Hájková; Jan Laco; Michal Mára; Adéla Richtárová; Tomáš Zima; Ivana Stružinská
Journal:  Virchows Arch       Date:  2021-10-09       Impact factor: 4.064

Review 2.  Leiomyoma with nuclear atypia: Rare diseases that present a common diagnostic problem.

Authors:  Jian-Jun Wei
Journal:  Semin Diagn Pathol       Date:  2022-02-02       Impact factor: 3.893

3.  Integrated histologic and molecular analysis of uterine leiomyosarcoma and 2 benign variants with nuclear atypia.

Authors:  Tingting Gao; Brian S Finkelman; Yanli Ban; Yinuo Li; Ping Yin; Serdar E Bulun; Xinyan Lu; Chunfang Ha; Jian-Jun Wei
Journal:  Cancer Sci       Date:  2021-03-22       Impact factor: 6.716

4.  Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation.

Authors:  Pier Selenica; Niamh Conlon; Carlene Gonzalez; Denise Frosina; Achim A Jungbluth; Regina G H Beets-Tan; Mamta K Rao; Yanming Zhang; Ryma Benayed; Marc Ladanyi; David B Solit; Sarah Chiang; David M Hyman; Martee L Hensley; Robert A Soslow; Britta Weigelt; Rajmohan Murali
Journal:  Am J Surg Pathol       Date:  2021-01       Impact factor: 6.394

5.  Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours.

Authors:  Michaela Bártů; Jan Hojný; Nikola Hájková; Romana Michálková; Eva Krkavcová; Ladislav Hadravský; Lenka Kleissnerová; Quang Hiep Bui; Ivana Stružinská; Kristýna Němejcová; Otakar Čapoun; Monika Šlemendová; Pavel Dundr
Journal:  Sci Rep       Date:  2020-10-13       Impact factor: 4.379

6.  HNF1B, EZH2 and ECI2 in prostate carcinoma. Molecular, immunohistochemical and clinico-pathological study.

Authors:  Pavel Dundr; Michaela Bártů; Jan Hojný; Romana Michálková; Nikola Hájková; Ivana Stružinská; Eva Krkavcová; Ladislav Hadravský; Lenka Kleissnerová; Jana Kopejsková; Bui Quang Hiep; Kristýna Němejcová; Radek Jakša; Otakar Čapoun; Jakub Řezáč; Kateřina Jirsová; Věra Franková
Journal:  Sci Rep       Date:  2020-09-01       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.